Download Prescription Form
Prescription required. I can submit a prescription
Out of stock
Adequan® i.m. (POLYSULFATED GLYCOSAMINOGLYCAN) is the only disease-modifying osteoarthritis drug on the market approved by the FDA for the treatment of non-infectious degenerative joint disease. It is the only joint therapy clinically proven to relieve symptoms and treat the underlying causes of equine degenerative joint disease.
* Studies show that administering Adequan® i.m. as recommended—500 mg intramuscularly once every four days for 28 days or seven treatments—better than results with four-injection series.
* Adequan® i.m. reaches the joint quickly. Two hours after a single i.m. injection, scintillation studies on multiple joints demonstrated beneficial levels in the synovial fluid of all joints tested.
The recomended dosage for Adequan® i.m. is 500 mg once every four days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan® i.m. with other drugs or solvents.
Adequan® i.m. vs. Legend® After six weeks of comparison to intravenous Legend® (INTRAVENOUS SODIUM HYALURONATE), Adequan® i.m. demonstrated, on average, a more rapid and significantly better recovery:
* Decreased lameness score
* Increased stride length
* Lowered joint flexing pain score
Adequan® i.m. is safe. You can be confident of the safety of Adequan® i.m. (POLYSULFATED GLYCOSAMINOGLYCAN). Based on clinical studies, field testing and its long safety record, there are no known contraindications for the intramuscular use of Adequan® i.m. No adverse effects were observed in clinical trials and toxicological studies in which Adequan® i.m. was administered intramuscularly at five times the recommended dose and for three times the recommended duration.
Studies have not been conducted to establish safety in breeding horses.
Choose: Multi-Dose 50 ml or Single Dose Vial 5 ml each